Artisan Partners Limited Partnership Makes New $7.40 Million Investment in Replimune Group, Inc. (NASDAQ:REPL)

Artisan Partners Limited Partnership acquired a new position in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 611,013 shares of the company's stock, valued at approximately $7,399,000. Artisan Partners Limited Partnership owned approximately 0.89% of Replimune Group as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of REPL. China Universal Asset Management Co. Ltd. increased its position in shares of Replimune Group by 24.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 16,317 shares of the company's stock worth $198,000 after purchasing an additional 3,177 shares in the last quarter. SG Americas Securities LLC grew its stake in shares of Replimune Group by 14.7% during the fourth quarter. SG Americas Securities LLC now owns 26,291 shares of the company's stock worth $318,000 after acquiring an additional 3,374 shares during the last quarter. MetLife Investment Management LLC increased its holdings in shares of Replimune Group by 21.5% during the third quarter. MetLife Investment Management LLC now owns 35,134 shares of the company's stock valued at $385,000 after acquiring an additional 6,216 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in shares of Replimune Group by 81.7% during the third quarter. BNP Paribas Financial Markets now owns 15,011 shares of the company's stock valued at $165,000 after acquiring an additional 6,748 shares in the last quarter. Finally, Rhumbline Advisers raised its position in shares of Replimune Group by 8.3% in the 4th quarter. Rhumbline Advisers now owns 95,465 shares of the company's stock valued at $1,156,000 after purchasing an additional 7,317 shares during the last quarter. Hedge funds and other institutional investors own 92.53% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

REPL has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. raised their price target on shares of Replimune Group from $16.00 to $18.00 and gave the stock an "overweight" rating in a report on Wednesday, February 26th. BMO Capital Markets increased their price objective on Replimune Group from $18.00 to $27.00 and gave the company an "outperform" rating in a report on Wednesday, January 22nd. HC Wainwright lifted their target price on Replimune Group from $21.00 to $22.00 and gave the stock a "buy" rating in a report on Thursday, February 13th. Finally, Jefferies Financial Group upped their target price on Replimune Group from $16.00 to $19.00 and gave the company a "buy" rating in a research report on Wednesday, December 4th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $19.43.

Replimune Group Stock Performance

Replimune Group stock traded down $0.64 during mid-day trading on Monday, hitting $9.75. The company had a trading volume of 913,431 shares, compared to its average volume of 858,501. The company has a market capitalization of $750.90 million, a price-to-earnings ratio of -3.18 and a beta of 1.30. Replimune Group, Inc. has a 12-month low of $4.92 and a 12-month high of $17.00. The company's fifty day moving average is $12.67 and its 200-day moving average is $12.17. The company has a current ratio of 11.43, a quick ratio of 11.43 and a debt-to-equity ratio of 0.14.

Replimune Group (NASDAQ:REPL - Get Free Report) last released its quarterly earnings data on Wednesday, February 12th. The company reported ($0.79) earnings per share for the quarter, missing analysts' consensus estimates of ($0.70) by ($0.09). Equities research analysts predict that Replimune Group, Inc. will post -2.97 EPS for the current year.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.